Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds

ABSTRACT

Disclosed herein are compounds represented by the structural formula: therapeutic methods, compositions, and medicaments related thereto are also disclosed.

RELATED APPLICATION

This application is a Continuation of U.S. patent application Ser. No.13/461,398, filed May 1, 2012, is a Continuation of U.S. patentapplication Ser. No. 13/150,751, filed Jun. 1, 2011, which is aContinuation of U.S. patent application Ser. No. 12/437,138, filed May7, 2009, to which claims priority to U.S. Provisional Application61/051,533, filed May 8, 2008, the disclosure of which are incorporatedby reference herein in their entirety

FIELD OF THE INVENTION

The present invention provides novel substitutedhydropyrido[3,2,1-ij]quinoline compounds, and their uses in medicamentsfor the treatment of mammals with diseases and conditions that arealleviated by sphingosine-1-phosphate (S1P) receptors modulation.

BACKGROUND OF THE INVENTION

Sphingosine is a compound having the chemical structure shown in thegeneral formula described below, in which Y¹ is hydrogen. It is knownthat various sphingolipids, having sphingosine as a constituent, arewidely distributed in the living body including on the surface of cellmembranes of cells in the nervous system.

A sphingolipid is one of the lipids having important roles in the livingbody. A disease called lipidosis is caused by accumulation of aspecified sphingolipid in the body. Sphingolipids present on cellmembranes function to regulate cell growth; participate in thedevelopment and differentiation of cells; function in nerves; areinvolved in the infection and malignancy of cells; etc. Many of thephysiological roles of sphingolipids remain to be solved. Recently thepossibility that ceramide, a derivative of sphingosine, has an importantrole in the mechanism of cell signal transduction has been indicated,and studies about its effect on apoptosis and cell cycle have beenreported.

Sphingosine-1-phosphate is an important cellular metabolite, derivedfrom ceramide that is synthesized de novo or as part of thesphingomeyeline cycle (in animals cells). It has also been found ininsects, yeasts and plants.

The enzyme, ceramidase, acts upon ceramides to release sphingosine,which is phosphorylated by sphingosine kinase, a ubiquitous enzyme inthe cytosol and endoplasmic reticulum, to form sphingosine-1-phosphate.The reverse reaction can occur also by the action of sphingosinephosphatases, and the enzymes act in concert to control the cellularconcentrations of the metabolite, which concentrations are always low.In plasma, such concentration can reach 0.2 to 0.9 μM, and themetabolite is found in association with the lipoproteins, especially theHDL. It should also be noted that sphingosine-1-phosphate formation isan essential step in the catabolism of sphingoid bases.

Like its precursors, sphingosine-1-phosphate is a potent messengermolecule that perhaps uniquely operates both intra- andinter-cellularly, but with very different functions from ceramides andsphingosine. The balance between these various sphingolipid metabolitesmay be important for health. For example, within the cell,sphingosine-1-phosphate promotes cellular division (mitosis) as opposedto cell death (apoptosis), which it inhibits. Intracellularly, it alsofunctions to regulate calcium mobilization and cell growth in responseto a variety of extracellular stimuli. Current opinion appears tosuggest that the balance between sphingosine-1-phosphate and ceramideand/or sphingosine levels in cells is critical for their viability.

In common with the lysophospholipids, especially lysophosphatidic acid,with which it has some structural similarities, sphingosine-1-phosphateexerts many of its extra-cellular effects through interaction with fivespecific G protein-coupled receptors on cell surfaces, known asendothelium differentiation gene receptors (“Edg” or “S1P” receptors).

S1P3 receptor is one of the receptors interacting withsphingosine-1-phosphate. S1P3 receptor, alone or together with other S1Preceptors, involves in many critical biological processes, such as thegrowth of new blood vessels, vascular maturation, cardiac developmentand immunity, as well as for directed cell movement. S1P3 receptormodulators are needed for therapeutic uses.

SUMMARY OF THE INVENTION

The compounds of the present invention can be represented by thestructural formula:

wherein m is an integer of 0, or 1; n is an integer of 0, 1, 2, or 3;each Y is independently carbon (C) or nitrogen (N); Z and X are eachindependently selected from the group of oxygen (O), sulfur (S), andamine moiety NR^(N); B is selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl,carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkylamide, amino, alkylamino, cyano and X—B together being a heterocyclicring or ring system; R and R³ are each independently selected from thegroup consisting of hydrogen, hydrocarbyl, heterohydrocarbyl,substituted or unsubstituted aryl, halo, halohydrocarbyl, hydroxyl,alkoxyl, hydroxyalkyl, alkylcarbonyl, carbonylalkyl, formyl,oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkyl amide, amino,alkylamino, and cyano; each R¹ is independently selected from the groupconsisting of hydrogen, hydrocarbyl, heterohydrocarbyl, substituted orunsubstituted aryl, halo, halohydrocarbyl, hydroxyl, alkoxyl,hydroxyalkyl, alkylcarbonyl, formyl, oxycarbonyl, aminocarbonyl,aminocarbonxyl, alkylcarboxyl, alkyl amide, amino, alkylamino, andcyano; each R² is independently selected from the group consisting ofhydrocarbyl, heterohydrocarbyl, substituted or unsubstituted aryl, halo,halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, formyl,oxo, oxycarbonyl, carboxyl, alkyl carboxylate, alkyl amide,aminocarbonyl, amino, alkylamino, and cyano; each R^(N) is independentlyselected from the group consisting of hydrogen, hydrocarbyl,heterohydrocarbyl, substituted or unsubstituted aryl, halohydrocarbyl,hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, carbonylalkyl, formyl,oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkyl amide, amino,alkylamino, and cyano; including their alternate solid forms, tautomers,stereoisomers, enantiomers, diastereomers, prodrugs, andpharmaceutically acceptable salts, hydrates and solvates; and providedthat when Y is carbon, and Z and X are both oxygen, R² is not oxo, or R¹and R² are not both phenyl or both methyl at the same time.

Applicants have discovered that these compounds modulatesphingosine-1-phosphate (S1P) receptor activity, in particularly inhibitS1P3 receptor. These compounds are useful for the treatment of mammals,including human beings, with a range of conditions and diseases that arealleviated by S1P modulation, such as ocular diseases and conditions(glaucoma, elevated intraocular pressure, dry eye, and opticalneurodegenerative diseases), cardiovascular diseases and conditions,pulmonary diseases and conditions, skin conditions, angiogenesis,inflammation, sepsis and pain.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are compounds represented by the structural formula:

wherein m is an integer of 0 or 1; n is an integer of 0, 1, 2, or 3;each Y is independently carbon (C) or nitrogen (N); Z and X are eachindependently selected from the group of oxygen (O), sulfur (S), andamine moiety NR^(N); B is selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl,carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkylamide, amino, alkylamino, cyano and X—B together being a heterocyclicring/ring system.

R and R³ are each independently selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halo, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl,alkylcarbonyl, carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkylcarboxyl, alkyl amide, amino, alkylamino, and cyano; each R¹ isindependently selected from the group consisting of hydrogen,hydrocarbyl, heterohydrocarbyl, substituted or unsubstituted aryl, halo,halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, formyl,oxycarbonyl, aminocarbonyl, aminocarbonxyl, alkylcarboxyl, alkyl amide,amino, alkylamino, and cyano; each R² is independently selected from thegroup consisting of hydrocarbyl, heterohydrocarbyl, substituted orunsubstituted aryl, halo, halohydrocarbyl, hydroxyl, alkoxyl,hydroxyalkyl, alkylcarbonyl, formyl, oxo, oxycarbonyl, carboxyl, alkylcarboxylate, alkyl amide, aminocarbonyl, amino, alkylamino, and cyano;each R^(N) is independently selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl,carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkylamide, amino, alkylamino, and cyano; including their alternate solidforms, tautomers, stereoisomers, enantiomers, diastereomers, prodrugs,and pharmaceutically acceptable salts, hydrates and solvates; andoptionally, provided that when Y is carbon, and Z and X are both oxygen,R² is not oxo, or R¹ and R² are not both phenyl or both methyl at thesame time.

It has been discovered that the compounds of the present inventionlisted in this patent application modulate sphingosine-1-phosphate (S1P)receptor activity and in particular the S1P3 receptor. These compoundsare useful for the treatment of mammals, including humans, with a rangeof conditions and diseases that are alleviated by S1P modulation: notlimited to treating glaucoma, elevated intraocular pressure, ischemicneuropathies, optic neuropathy, pain, visceral pain, corneal pain,headache pain, migraine, cancer pain, back pain, irritable bowelsyndrome pain, muscle pain and pain associated with diabetic neuropathy,the treatment of diabetic retinopathy, other retinal degenerativeconditions, dry eye, angiogenesis and wounds. Other uses include:

Ocular Applications:

Retinopathy of prematurity, diabetic retinopathy, optic neuropathy,glaucomatous retinopathy, macular degeneration, choroidalneovascularization, ocular wound healing, and retinal edema;

Cardiovascular Applications:

Congestive heart failure, cardiac arrhythmia, atherosclerosis, andbradycardia;

Pulmonary Applications:

Asthma, chronic obstructive pulmonary disease, acute lung injury, acuterespiratory distress syndrome, idiopathic pulmonary fibrosis, andventilation-induced lung injury; and,

Skin Applications:

Scar-less wound healing, scar-less skin-wound and cosmetic healing.

For the purposes of this disclosure, “treat,” “treating,” or “treatment”refer to the diagnosis, cure, mitigation, treatment, or prevention ofdisease or other undesirable condition.

The compounds of present invention may be identified either by theirchemical structures and/or chemical names. If the chemical structure andthe chemical name conflict, the chemical structure is determinative ofthe identity of the compound.

The compounds of the invention may contain one or more chiral centersand/or double bonds and therefore, may exist as stereoisomers, such asdouble-bond isomers, enantiomers or diastereomers. Accordingly, thechemical structures depicted herein encompass all possible enantiomersand stereoisomers, including the stereoisomerically pure form andenantiomeric and stereoisomeric mixtures. The compounds of the inventionmay also exist in several tautomeric forms, including but not limitingto, the enol form, the keto form and mixtures thereof. Accordingly, thechemical structures depicted herein encompass all possible tautomericforms. The compounds of the invention also include isotopically labeledcompounds where one or more atoms have an atomic mass different from theatomic mass conventionally found in nature.

Further, the compounds of the invention should be construed broadly toinclude their pharmaceutically acceptable salts, prodrugs, alternatesolid forms, non-covalent complexes, and combinations thereof, unlessotherwise indicated.

A pharmaceutically acceptable salt is any salt of the parent compoundthat is suitable for administration to a mammal, including human. Apharmaceutically acceptable salt also refers to any salt which may formin vivo as a result of administration of an acid, another salt, or aprodrug which is converted into an acid or salt. A salt comprises one ormore ionic forms of the compound, such as a conjugate acid or base,associated with one or more corresponding counter-ions. Salts can formfrom or incorporate one or more deprotonated acidic groups (e.g.carboxylic acids), one or more protonated basic groups (e.g. amines), orboth (e.g. zwitterions).

A prodrug is a compound which is converted to a therapeutically activecompound after administration. For example, conversion may occur byhydrolysis of an ester group or some other biologically labile groups.Prodrug preparation is well known in the art. For example, “Prodrugs andDrug Delivery Systems,” which is a chapter in Richard B. Silverman,Organic Chemistry of Drug Design and Drug Action, 2d Ed., ElsevierAcademic Press: Amsterdam, 2004, pp. 496-557, provides further detail onthis subject.

Alternate solid forms are different solid forms than those that mayresult from practicing the procedures described herein. For example,alternate solid forms may be polymorphs, different kinds of amorphoussolid forms, glasses, and the like.

Non-covalent complexes are complexes that may form between the compoundand one or more additional chemical species that do not involve acovalent bonding interaction between the compound and the additionalchemical species. They may or may not have a specific ratio between thecompound and the additional chemical species. Examples include solvates,hydrates, charge transfer complexes, and the like.

Hydrocarbyl consists of carbon and hydrogen, wherein each carbon has 4covalent bonds and each hydrogen has a single bond to a carbon atom.“Hydrocarbyl fragments” has the same meaning as “hydrocarbyl,” but ismerely used for convenience for counting purposes. For example, one ormore hydrocarbyl fragments means, 1, 2, or more distinct parts that eachconsists of hydrocarbyl, which may be interrupted by another moiety. Forexample, a functional group may be attached to 2 distinct hydrocarbylfragments.

Hydrocarbyl includes alkyl, alkenyl, alkynyl, aryl containing onlyhydrogen and carbon, and combinations thereof. Hydrocarbyl may belinear, branched, cyclic (aromatic or non-aromatic), or combinationsthereof, which can be further substituted.

Alkyl is a hydrocarbyl having no double bonds. Examples include methyl,ethyl, propyl isomers, butyl isomers, pentyl isomers, hexyl isomers,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

Alkenyl is a hydrocarbyl having one or more double bonds. Examplesinclude ethenyl, propenyl, butenyl isomers, pentenyl isomers, hexenylisomers, cyclopentenyl, cyclohexenyl, etc.

Alkynyl is a hydrocarbyl having one or more triple bonds. Examplesinclude ethynyl, propynyl, butynyl isomers, pentynyl isomers, hexynylisomers, cyclopentynyl, cyclohexynyl, etc.

Aryl is a substituted or unsubstituted aromatic ring or ring system. Itcan be hydrocarbon-aryl or heteroaryl. Examples of hydrocarbon-arylinclude substituted and unsubstituted phenyl, naphthyl, and biphenyl.Such aryl group can be bonded to other moieties within the molecule atany position.

Each hydrogen atom has one covalent bond to carbon (C), nitrogen (N),oxygen (O), or sulfur (S).

Halo or halo atoms are fluorine (F), chlorine (Cl), bromine (Br), andiodine (I). Each halo atom forms a single bond to a carbon atom.Halohydrocarbyl is a hydrocarbyl having one or more F, Cl, Br, or I assubstituents.

Heterohydrocarbyl refers to a hydrocarbyl as defined above with at leastone non-carbon atom(s) presented at the backbone, including but notlimiting to, oxygen (O), sulfur (S), nitrogen (N), phosphor (P), andhalo atoms. Heterohydrocarbyl may be linear, branched, cyclic (aromaticor non-aromatic), or combinations thereof, which can be furthersubstituted.

Examples of heterohydrocarbyl include: —R¹⁰-G¹-R¹¹, R¹⁰-HI, -G¹-R¹⁰,-G¹-R¹⁰-HI, G¹-R¹⁰-G², and G¹-R¹⁰-G²-R¹¹, wherein R¹⁰ and R¹¹ areindependently hydrocarbyl or hydrogen (provided that hydrogen isattached to only one C, N, O, or S atom), G¹ and G² are independentlyfunctional groups, and HI is halo.

Additional examples of heterohydrocarbyl are depicted below, whereinR¹⁰, R¹¹, R¹², and R¹³ are independently hydrocarbyl or hydrogen. Otherpossibilities exist, but are not depicted here.

Heteroaryl is one type of heterohydrocarbyl, referring to an aromaticring or ring system containing at least one hetero atom selected from N,O, S, P, and combinations thereof. Examples of heteroaryl include, butnot limit to, pyridine, pyrazine, pyrimidine, pyridazine, triazine,furan, pyrrole, thiophene, imidazole, pyrazole, oxazole, isoxazole,thiazole, isothiazole, oxadiazole, thiadiazole, naphthalene, quinoline,quinoxaline, quinazoline, cinnoline, isoquinoline, benzofuran, indole,benzothiophene, benzimidazole, indazole, benzoxazole, benzisoxazole,benzothiazole, isobenzofuran, isoindole, tetraline, chromane,isochromane, thiochromane, chromene, isochromene, thiochromene, indane,indene, coumarine, coumarinone, and the like, which can be furthersubstituted. Such heteroaryl group can be bonded to other moietieswithin the molecule at any position.

“Substituted” or “a substituent” is hydrogen, one or more hydrocarbylfragments, one or more heterohydrocarbyl fragments, one or more haloatoms, one or more functional groups, or combinations thereof. Two ormore substituents may themselves form an additional ring or ring system.

A functional group comprises of alkyl, aryl, alkenyl, alkynyl, halo,haloalkyl, hydroxyl, alkoxyl, hydroxyalkyl, oxo, alkylcarbonyl, formyl,carboxyl, alkylcarboxylate, alkylamide, aminocarbonyl, amino, cyano,diazo, nitro, thio, sulfoxyl, sulfonyl, phosphate, phosphinate, and oneof the moieties depicted below.

If a functional group is asymmetric, it may be oriented in any waypossible. For example, the ester functional group is intended toindicate both of the structures below.

In a substituent, one or more hydrocarbyl fragments, one or moreheterohydrocarbyl fragments, and/or one or more functional groups may beincorporated into one or more rings or ring systems.

The dashed lines on the functional groups indicate that any nitrogenatom on a functional group may form an additional bond with anothercarbon atom, a hydrogen atom, or may form a double bond with one of thedepicted bonds so that an ammonium or a quaternary ammonium type offunctional group is formed. Thus, the dashed line functional groupsactually represent a group of individual functional groups. For example,the functional group:

represents the following possible structures:

Similarly, the functional group:

represents the following possible structures:

In one embodiment, compounds of the invention are represented by thestructural formula

wherein m is an integer of 0, or 1; n is an integer of 0, 1, 2, or 3;

Z and X are each independently selected from the group of oxygen sulfur,and amine moiety NR^(N);

B is selected from the group consisting of hydrogen, hydrocarbyl,heterohydrocarbyl, substituted or unsubstituted aryl, halohydrocarbyl,hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, carbonylalkyl, formyl,oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkyl amide, amino,alkylamino, cyano and X—B together being a heterocyclic ring or ringsystem;

R and R³ are each independently selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halo, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl,alkylcarbonyl, carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkylcarboxyl, alkyl amide, amino, alkylamino, and cyano;

each R¹ is independently selected from the group consisting of hydrogen,hydrocarbyl, heterohydrocarbyl, substituted or unsubstituted aryl, halo,halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, formyl,oxycarbonyl, aminocarbonyl, aminocarbonxyl, alkylcarboxyl, alkylalkylcarbonyl, formyl, oxycarbonyl, aminocarbonyl, aminocarbonxyl,alkylcarboxyl, alkyl amide, amino, alkylamino, and cyano;

each R² is independently selected from the group consisting ofhydrocarbyl, heterohydrocarbyl, substituted or unsubstituted aryl, halo,halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, formyl,oxo, oxycarbonyl, carboxyl, alkyl carboxylate, alkyl amide,aminocarbonyl, amino, alkylamino, and cyano; each R^(N) is independentlyselected from the group consisting of hydrogen, hydrocarbyl,heterohydrocarbyl, substituted or unsubstituted aryl, halohydrocarbyl,hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, carbonylalkyl, formyl,oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkyl amide, amino,alkylamino, and cyano; including their alternate solid forms, tautomers,stereoisomers, enantiomers, diastereomers, prodrugs, andpharmaceutically acceptable salts, hydrates and solvates.

In another embodiment, compounds of the invention are represented by thestructural formula

wherein

n is 0, 1, 2, or 3;

Z is O, S, or NR^(N);

X is O, S, or NR^(N);

B is selected from the group consisting of hydrogen, hydrocarbyl,heterohydrocarbyl, substituted or unsubstituted aryl, halohydrocarbyl,hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, carbonylalkyl, formyl,oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkyl amide, amino,alkylamino, cyano and X—B together being a heterocyclic ring;

R and R³ are each independently selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halo, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl,alkylcarbonyl, carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkylcarboxyl, alkyl amide, amino, alkylamino, and cyano;

each R¹ is independently selected from the group consisting of hydrogen,hydrocarbyl, heterohydrocarbyl, substituted or unsubstituted aryl, halo,halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, formyl,oxycarbonyl, aminocarbonyl, aminocarbonxyl, alkylcarboxyl, alkyl amide,amino, alkylamino, and cyano;

each R² is independently selected from the group consisting ofhydrocarbyl, heterohydrocarbyl, substituted or unsubstituted aryl, halo,halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, formyl,oxo, oxycarbonyl, carboxyl, alkyl carboxylate, alkyl amide,aminocarbonyl, amino, alkylamino, and cyano;

each R^(N) is independently selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl,carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkyl carboxyl, alkylamide, amino, alkylamino, and cyano;

including its alternate solid forms, tautomers, stereoisomers,enantiomers, diastereomers, prodrugs, and pharmaceutically acceptablesalts, hydrates and solvates.

In yet another embodiment, the compounds are represented by

wherein o is an integer of 0, 1, 2, or 3;Z is O or S;each R^(A) is independently selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halo, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl,alkylcarbonyl, carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkylcarboxyl, alkyl amide, amino, alkylamino, and cyano;R and R³ are each independently selected from the group consisting ofhydrogen and a substituent having a formulaC₀₋₁₂H₀₋₃₀N₀₋₃O₀₋₅P₀₋₂S₀₋₃F₀₋₆Cl₀₋₃Br₀₋₃I₀₋₃;each R^(N) is independently selected from the group consisting ofhydrogen and C₁₋₁₂ hydrocarbyl;B is selected from the group consisting of hydrogen, a substituenthaving a formula C₀₋₁₂H₀₋₃₀N₀₋₃O₀₋₅P₀₋₂S₀₋₃F₀₋₆Cl₀₋₃Br₀₋₃I₀₋₃, whereinif X is NR^(N), and X—B being a heterocyclic ring/ring system. Theformula C₀₋₁₂H₀₋₃₀N₀₋₃O₀₋₅P₀₋₂S₀₋₃F₀₋₆Cl₀₋₃Br₀₋₃I₀₋₃ represents astructure having from 0-12 carbon atoms, from 0-30 hydrogen atoms, from0-3 nitrogen atoms, from 0-5 oxygen atoms, from 0-2 phosphorous atoms,from 0-3 sulfur atoms, from 0-6 fluorine atoms, from 0-3 chlorine atoms,from 0-3 bromine atoms, and from 0-3 iodine atoms.

In yet another embodiment, each R^(A) is independently hydrogen, alkyl,aryl, alkenyl, alkynyl, halo, haloalkyl, hydroxyl, alkoxyl,hydroxyalkyl, alkylcarbonyl, formyl, carboxyl, alkyl carboxylate, alkylamide, aminocarbonyl, amino, cyano, diazo, nitro, thio, sulfoxyl,sulfonyl, phosphate, or phosphinate.

In another embodiment, X is O.

In another embodiment, Z is O.

In another embodiment, Z is S.

In another embodiment, B is C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, C₁₋₆haloalkyl, hydroxyalkyl, phenyl, benzyl, furylmethyl, or wherein X—B ismorpholino. C₁₋₆ means having from one to six (1-6) carbon atoms. C₁₋₆haloalkyl is C₁₋₆ alkyl having at least one halo atoms of F, Cl, Br, orI as the substituent. Examples of haloalkyl include —CH2F, —CH₂CHF₂,—C₃H₆F, —C₄H₈F, —C₅H₁₀F, —C₆H₁₂F, fluorocyclopropyl, fluorocyclobutyl,fluorocyclopentyl, fluorocyclohexyl, —CH₂CH₂Cl, —C₃H₆Cl, —C₄H₈Cl,—C₆H₁₀Cl, —C₆H₁₂Cl, chlorocyclopropyl, chlorocyclobutyl,chlorocyclopentyl, chlorocyclohexyl, —CH₂CH₂Br, —C₃H₆Br, —C₄H₈Br,—C₆H₁₀Br, —C₆H₁₂Br, bromocyclopropyl, bromocyclobutyl, bromocyclopentyl,bromocyclohexyl, —CH₂CH₂I, —C₃H₆I, —C₄H₈I, —C₆H₁₀I, —C₆H₁₂I,iodocyclopropyl, iodocyclobutyl, iodocyclopentyl, and iodocyclohexyl.Morpholino is:

In another embodiment, R^(A) is hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkenyl,C₁₋₁₂ alkynyl, halo, C₁₋₁₂ halohydrocarbyl, C₁₋₁₂ hydroxyalkyl, C₃₋₁₂cyclic hydrocarbyl, or heteroaryl. C₁₋₁₂ means having from 1-12 carbonatoms.

In yet another embodiment, X is NR^(N).

In another embodiment, the compounds can be represented by thestructural formula:

wherein each R^(A) is independently hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂alkenyl, C₁₋₁₂ alkynyl, halo, C₁₋₁₂ halohydrocarbyl, C₁₋₁₂ hydroxyalkyl,C₃₋₁₂ cyclic hydrocarbyl, or heteroaryl.

In another embodiment, R^(N) is hydrogen, methyl, ethyl, propyl, orisopropyl.

In one embodiment, R^(N) is hydrogen, C₁₋₆ alkyl or phenyl.

In another embodiment, B is hydrocarbyl, as described above.

In yet another embodiment, B is substituted or unsubstitutedhydrocarbon-aryl or heterohydrocarbyl. Examples of heteroaryl includepyridine, pyrazine, pyrimidine, pyridazine, triazine, furan, pyrrole,thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole,isothiazole, oxadiazole, thiadiazole, naphthalene, quinoline,quinoxaline, quinazoline, cinnoline, isoquinoline, benzofuran, indole,benzothiophene, benzimidazole, indazole, benzoxazole, benzisoxazole,benzothiazole, isobenzofuran, isoindole, tetraline, chromane,isochromane, thiochromane, chromene, isochromene, thiochromene, indane,indene, coumarine, coumarinone, and the like.

If the aryl or heteroaryl is substituted, the substituents are the sameas those defined above. Examples include alkyl, aryl, alkenyl, alkynyl,halo, haloalkyl, hydroxyl, alkoxyl, hydroxyalkyl, alkylcarbonyl, formyl,carboxyl, alkyl carboxylate, alkyl amide, aminocarbonyl, amino, cyano,diazo, nitro, thio, sulfoxyl, sulfonyl, phosphate, phosphinate, and thelike.

B may also be a combination of one or more of hydrogen, hydrocarbyl,heterohydrocarbyl, substituted or unsubstituted hydrocarbon-aryl, orsubstituted or unsubstituted heteroaryl. For example, B may have one ofthe structures shown below:

Compounds according to the structural formulas below are alsocontemplated:

wherein o is an integer of 0, 1, 2, or 3; Z is O or S;each R^(A) is independently selected from the group consisting ofhydrogen, hydrocarbyl, heterohydrocarbyl, substituted or unsubstitutedaryl, halo, halohydrocarbyl, hydroxyl, alkoxyl, hydroxyalkyl,alkylcarbonyl, carbonylalkyl, formyl, oxycarbonyl, aminocarbonyl, alkylcarboxyl, alkyl amide, amino, alkylamino, and cyano;R and R³ are each independently selected from the group consisting ofhydrogen and a substituent having a formulaC₀₋₁₂H₀₋₃₀N₀₋₃O₀₋₅P₀₋₂S₀₋₃F₀₋₆Cl₀₋₃Br₀₋₃I₀₋₃;each R^(N) is independently selected from the group consisting ofhydrogen and C₁₋₁₂ hydrocarbyl;B is selected from the group consisting of hydrogen, a substituenthaving a formula C₀₋₁₂H₀₋₃₀N₀₋₃O₀₋₅P₀₋₂S₀₋₃F₀₋₆Cl₀₋₃Br₀₋₃I₀₋₃, whereinif X is NR^(N), and X—B being a heterocyclic ring/ring system. Theformula C₀₋₁₂H₀₋₃₀N₀₋₃C₀₋₅P₀₋₂S₀₋₃F₀₋₆Cl₀₋₃Br₀₋₃I₀₋₃ represents astructure having from 0-12 carbon atoms, from 0-30 hydrogen atoms, from0-3 nitrogen atoms, from 0-5 oxygen atoms, from 0-2 phosphorous atoms,from 0-3 sulfur atoms, from 0-6 fluorine atoms, from 0-3 chlorine atoms,from 0-3 bromine atoms, and from 0-3 iodine atoms.

In yet another embodiment, each R^(A) is independently hydrogen, alkyl,aryl, alkenyl, alkynyl, halo, haloalkyl, hydroxyl, alkoxyl,hydroxyalkyl, alkylcarbonyl, formyl, carboxyl, alkyl carboxylate, alkylamide, aminocarbonyl, amino, cyano, diazo, nitro, thio, sulfoxyl,sulfonyl, phosphate, or phosphinate.

In another embodiment, X is O.

In another embodiment, Z is O.

In another embodiment, Z is S.

In another embodiment, B is C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkynyl, C₁₋₆haloalkyl, hydroxyalkyl, phenyl, benzyl, furylmethyl, or wherein X—B ismorpholino. C₁₋₆ means having from one to six (1-6) carbon atoms. C₁₋₆haloalkyl is C₁₋₆ alkyl having at least one halo atoms of F, Cl, Br, orI as the substituent. Examples of haloalkyl include —CH2F, —CH₂CHF₂,—C₃H₆F, —C₄H₈F, —C₅H₁₀F, —C₆H₁₂F, fluorocyclopropyl, fluorocyclobutyl,fluorocyclopentyl, fluorocyclohexyl, —CH₂CH₂Cl, —C₃H₆Cl, —C₄H₈Cl,—C₅H₁₀Cl, —C₆H₁₂Cl, chlorocyclopropyl, chlorocyclobutyl,chlorocyclopentyl, chlorocyclohexyl, —CH₂CH₂Br, —C₃H₆Br, —C₄H₈Br,—C₅H₁₀Br, —C₆H₁₂Br, bromocyclopropyl, bromocyclobutyl, bromocyclopentyl,bromocyclohexyl, —CH₂CH₂I, —C₃H₆I, —C₄H₈I, —C₅H₁₀I, —C₆H₁₂I,iodocyclopropyl, iodocyclobutyl, iodocyclopentyl, iodocyclohexyl

Specific compounds of the present invention include:

The compounds of the present invention can be combined with at least oneother therapeutic agent that is already known the art. The compounds ofinvention and the other therapeutic agent(s) can act additively, or morepreferably, synergistically.

The invention is further defined by reference to the following examples,which describe the preparation schemes and methods for obtaining thecompounds of the invention, the assays for testing the biologicalactivities of these compounds. It will be apparent to those skilled inthe art that many modifications, both to the preparation schemes andassays, may be practiced without departing from the scope of theinvention.

EXAMPLES Organic Synthesis

Reaction Schemes A, B, C, D and E are examples of the preparationmethods for obtaining the compounds of the invention.

Example A Method A1: Preparation of methyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate(272)

To a solution 4-Nitroaniline (Intermediate 1) (1.8 g, 10 mmol) inacetonitrile (8 mL) was added one equivalent of trifluoroacetic acid(1.14 g, 10 mmol). To this suspension was added with stirring aheterogeneous mixture of styrene (Intermediate 2), (5.74 mL, 50 mmol)and 37% formaldehyde solution (4.06 mL, 50 mmol) under argon, which gavea yellow precipitate. The precipitate failed to re-dissolve after 30min. of stirring at room temperature, so the mixture was heated atreflux under argon for further 30 min, during which time the precipitatere-dissolved. The reaction mixture was cooled to room temperature. Theprecipitate was filtered and wash with acetonitrile gave yellow solid,9-nitro-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline(Intermediate 3), (1.53 g, 41%).

A solution of9-nitro-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline(Intermediate 3), (1.2 g, 7.06 mmol), in MeOH (100 mL) was subjected tohydrogenation reaction by the action of 10% Pd/C (120 mg) under H₂balloon at room temperature for 12 h. The mixture was filtered throughCelite and freed of solvent under reduced pressure to get1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-amine(Intermediate 4) as a solid, (1.08 g, 98%).

To a solution1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-amine(Intermediate 4), (207 mg, 0.608 mmol) in dichloromethane (10 mL) wasadded three equivalent of triethyl amine (0.252 mL, 1.8 mmol), followedby methyl chloroformate (0.071 mL, 0.91 mmol) under argon at 0° C. Thereaction mixture was then stirred at room temperature for overnight. Themixture was quenched with water (30 mL). The residue was isolated in atypical aqueous workup and purified by MPLC (medium pressure liquidchromatography) using silica gel column with 10 to 15% EtOAc:Hexane togive methyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate(272), (181 mg 75%). ¹H NMR (300 MHz, CDCl₃) δ ppm 2.00-2.18 (m, 2H)2.22-2.39 (m, 2H) 3.03-3.22 (m, 4H) 3.50-3.64 (m, 3H) 3.54-3.65 (m, 3H)4.05-4.23 (m, 2H) 6.61 (br. s., 2H) 7.08-7.38 (m, 10H).

Method A2: Preparation of methyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,(829), and methyl(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate(353)

To a solution 4-Nitroaniline (1) (4.1 g, 30 mmol) in acetonitrile (30mL) was added one equivalent of trifluoroacetic acid (2.3 mL, 30 mmol).To this suspension was added with stirring a heterogeneous mixture ofstyrene (2), (19.4 mL, 150 mmol) and 37% formaldehyde solution (12.2 mL,150 mmol) under argon gave yellow precipitate. The precipitate hadfailed to re-dissolve after 30 min. of stirring at room temperature, sothe mixture was heated at reflux under argon for further 30 min, duringwhich time the precipitate re-dissolved. The reaction mixture was cooledto room temperature. After general workup afforded mixture of threeintermediates 3 (836 mg), 4 (2 g), and 5 (4.2 g), confirmed by MassSpectra and ¹HNMR (see ref. John M. Mellor; et al; Tetrahedron, 1995,6115). These intermediates were then converted into the cycloadductproduct by heating at reflux with trifluoroacetic acid in acetonitrileyielded1,7-dimethyl-9-nitro-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline(6) (7.036 g, 59%) as a solid. This solid product (6) was then separatedto trans and cis isomers by washing with ether gave trans (7), (4.0 g)and hexane:CH₂Cl₂ gave cis (8), (2.8 g).

A mixture of(1S,7S)-1,7-dimethyl-9-nitro-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline(7), (2 g, 5 mmol), in THF (60 mL) was subjected to hydrogenationreaction by the action of 10% Pd/C (200 mg) under H₂ balloon at roomtemperature for 12 h. The mixture was filtered through Celite and freedof solvent under reduced pressure to get(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-amine(9) as a solid, (1.5 g, 100%) on the basis of recovered startingmaterial (7), (390 mg).

Following a procedure similar to that for (9) gained(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-amine(10) as a solid (2.55 g, 100% yield) from (8).

To a solution(1S,7S)-1,7-dimethyl-9-nitro-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline(7), (115 mg, 0.31 mmol), in dichloromethane (15 mL) was added threeequivalent of triethyl amine (0.129 mL, 0.93 mmol), followed by methylchloroformate (0.031 mL, 0.406 mmol) under argon at 0° C. The reactionmixture was then stirred at room temperature for overnight. The mixturewas quenched with water (30 mL). The residue was isolated in a typicalaqueous workup and purified by MPLC (medium pressure liquidchromatography) using silica gel column with 10 to 15% EtOAc:Hexane togive methyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate(829), (69 mg 52%). 1H NMR (300 MHz, Acetone-d6) ppm 1.72 (s, 6H)1.89-2.03 (m, 2H) 2.17-2.30 (m, 2H) 2.73-2.88 (m, 2H) 2.92-3.03 (m, 2H)3.56 (s, 3H) 7.05-7.33 (m, 12H) 8.02 (br. s., 1H).

Following a procedure similar to that for (829), gained(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate(353), (130 g, 62% yield) from (10). 1H NMR (300 MHz, Acetone-d6) δ ppm1.74 (s, 6H) 1.98-2.10 (m, 2H) 2.13-2.24 (m, 2H) 2.78-2.92 (m, 2H)2.92-3.05 (m, 2H) 3.55 (s, 3H) 7.06 (s, 2H) 7.12-7.34 (m, 10H) 8.02 (br.s., 1H).

The following compounds were prepared according to the Reaction Scheme Aand with the steps as shown in Example A above.

Ethyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,273

¹H NMR (300 MHz, CDCl₃) δ ppm 1.11 (t, J=7.03 Hz, 3H) 2.02-2.17 (m, 2H)2.21-2.37 (m, 2H) 3.04-3.17 (m, 4H) 4.04 (q, 2H) 4.09-4.21 (m, 2H) 6.61(br. s., 2H) 7.08-7.39 (m, 10H)

Isobutyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,274

¹H NMR (300 MHz, CDCl₃) δ ppm 0.94 (d, J=6.74 Hz, 6H) 1.84-2.02 (m, 1H)2.02-2.17 (m, 2H) 2.20-2.37 (m, 2H) 3.31-3.22 (m, 4H) 4.19-4.14 (m, 2H)6.63 (br. s., 2H) 7.11-7.24 (m, 5H) 7.25-7.37 (m, 5H)

Propyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,275

¹H NMR (300 MHz, CDCl₃) δ ppm 0.85 (t, J=6.89 Hz, 3H) 1.46-1.64 (m, 2H)2.00-2.18 (m, 2H) 2.21-2.37 (m, 2H) 3.03-3.19 (m, 4H) 3.88-4.00 (m, 2H)4.09-4.23 (m, 2H) 6.61 (br. s., 2H) 7.07-7.37 (m, 10H)

Butyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,276

¹H NMR (300 MHz, CDCl₃) δ ppm 0.87 (t, J=7.0 Hz, 3H) 1.30 (br. s., 2H)1.42-1.56 (m, 2H) 2.02-2.17 (m, 2H) 2.19-2.39 (m, 2H) 3.03-3.17 (m, 4H)3.91-4.03 (m, 2H) 4.10-4.22 (m, 2H) 6.61 (br. s., 2H) 7.08-7.38 (m, 10H)

Phenyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,277

¹H NMR (300 MHz, CDCl₃) δ ppm 2.05-2.19 (m, 2H) 2.21-2.40 (m, 2H)3.04-3.20 (m, 4H), 4.11-4.24 (m, 2H) 6.71 (br. s., 2H) 6.99-7.44 (m,15H)

Benzyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,278

¹H NMR (300 MHz, CDCl₃) δ ppm 1.91-2.09 (m, 2H) 2.10-2.29 (m, 2H)2.93-3.13 (m, 4H) 4.01-4.15 (m, 2H) 4.92 (s, 2H) 6.56 (br. s., 2H)7.01-7.32 (m, 15H)

Propyl1,7-bis(3-fluorophenyl)-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,094

1H NMR (300 MHz, CD₃OD) δ ppm 0.89 (t, 7.0 Hz, H) 1.47-1.67 (m, 2H)1.99-2.14 (m, 2H) 2.19-2.37 (m, 2H) 3.08 (t, J=5.71 Hz, 4H) 3.91 (t,J=6.74 Hz, 2H) 4.17 (t, J=6.01 Hz, 2H) 6.67 (br. s., 2H) 6.81-7.04 (m,6H) 7.22-7.38 (m, 2H)

Ethyl1,7-bis(3-fluorophenyl)-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,093

1H NMR (300 MHz, CD₃OD) δ ppm 1.15 (t, 7.0 Hz, H) 1.98-2.16 (m, 2H)2.18-2.37 (m, 2H) 2.96-3.18 (m, 4H) 4.00 (q, J=7.13 Hz, 2H) 4.19 (t,J=5.86 Hz, 2H) 6.68 (br. s., 2H) 6.77-7.01 (m, 6H) 7.20-7.35 (m, 2H)

Butyl1,7-bis(3-fluorophenyl)-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,202

1H NMR (300 MHz, Acetone-d₆) δ ppm 0.86 (t, 7.0 Hz, 6H) 1.20-1.39 (m,2H) 2.06-2.15 (m, 2H) 2.21-2.39 (m, 2H) 3.02-3.17 (m, 4H) 3.94 (t,J=6.59 Hz, 2H) 4.22 (t, J=5.86 Hz, 2H) 6.83 (br. s., 2H) 6.88-7.09 (m,6H) 7.28-7.42 (m, 2H)

Methyl1,7-bis(3-fluorophenyl)-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,779

1H NMR (300 MHz, CD₃OD) δ ppm 2.01-2.15 (m, 2H) 2.21-2.37 (m, 2H) 3.09(t, J=5.71 Hz, 4H) 3.57 (s, 3H) 4.18 (t, J=6.15 Hz, 2H) 6.67 (s, 2H)6.81-7.03 (m, 6H) 7.25-7.38 (m, 2H)

2-fluoroethyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,095

1H NMR (300 MHz, CD₃OD) δ ppm 1.99-2.16 (m, 2H) 2.19-2.36 (m, 2H)3.00-3.16 (m, 4H) 4.09-4.27 (m, 4H) 4.29-4.36 (m, 1H) 4.46-4.52 (m, 1H)6.66 (br. s., 2H) 7.07-7.21 (m, 6H) 7.21-7.33 (m, 4H)

But-3-enyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,354

1H NMR (300 MHz, Acetone-d₆) δ ppm 2.04-2.15 (m, 2H) 2.18-2.41 (m, 4H)3.02-3.18 (m, 4H) 3.89-4.01 (m, 2H) 4.90-5.14 (m, 2H) 5.69-5.88 (m, 1H)6.78 (br. s., 2H) 7.08-7.25 (m, 6H) 7.23-7.38 (m, 4H)

But-2-ynyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,353

1H NMR (300 MHz, Acetone-d₆) δ ppm 1.74 (s, 3H) 2.06-2.13 (m, 2H)2.19-2.34 (m, 2H) 3.02-3.20 (m, 4H) 4.19 (t, J=6.01 Hz, 2H) 4.52 (q,J=2.54 Hz, 2H) 6.78 (s, 2H) 7.12-7.24 (m, 6H) 7.26-7.35 (m, 4H)

Prop-2-ynyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,352

1H NMR (300 MHz, Acetone-d₆) δ ppm 2.05-2.15 (m, 2H) 2.20-2.36 (m, 2H)2.90 (t, J=2.49 Hz, 1H) 3.00-3.20 (m, 4H) 4.19 (t, J=6.01 Hz, 2H) 4.59(d, J=2.34 Hz, 2H) 6.78 (s, 2H) 7.11-7.24 (m, 6H) 7.25-7.37 (m, 4H)

4-chlorobutyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,206

1H NMR (300 MHz, Acetone-d₆) δ ppm 1.66-1.96 (m, 4H) 2.06-2.11 (m, 2H)2.22-2.32 (m, 2H) 3.04-3.17 (m, 4H) 3.58 (t, J=6 Hz, 2H) 3.96 (t, J=6.3Hz, 2H) 4.19 (t, J=6.3 Hz, 2H) 6.77 (s, 2H) 7.16-7.20 (m, 6H) 7.22-7.33(m, 4H)

3-chloropropyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,205

1H NMR (300 MHz, CD₃OD) δ ppm 1.91-2.14 (m, 4H) 2.20-2.34 (m, 2H)3.02-3.15 (m, 4H) 4.07 (t, J=6.01 Hz, 2H) 4.11-4.21 (m, 2H) 6.64 (br.s., 2H) 7.09-7.21 (m, 6H) 7.23-7.31 (m, 4H)

Ethyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,941

1H NMR (300 MHz, Acetone-d6) δ ppm 1.16 (t, J=7.18 Hz, 3H) 1.74 (s, 6H)1.90-2.01 (m, 2H) 2.16-2.32 (m, 2H) 2.73-2.89 (m, 2H) 2.90-3.03 (m, 2H)4.02 (q, J=7.13 Hz, 2H) 7.06-7.32 (m, 12H) 8.02 (br. s., 1H)

Propyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,942

1H NMR (300 MHz, Acetone-d6) δ ppm 0.88 (t, J=7.33 Hz, 3H) 1.46-1.65 (m,2H) 1.72 (s, 6H) 1.88-2.03 (m, 2H) 2.18-2.32 (m, 2H) 2.70-2.88 (m, 2H)2.89-3.03 (m, 2H) 3.94 (t, J=6.59 Hz, 2H) 7.06-7.33 (m, 12H) 8.02 (br.s., 1H)

Butyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,943

1H NMR (300 MHz, Acetone-d6) δ ppm 0.88 (t, J=7.33 Hz, 3H) 1.27-1.42 (m,1H) 1.45-1.61 (m, 1H) 1.67-1.77 (s, 6H) 1.88-2.03 (m, 2H) 2.18-2.31 (m,2H) 2.72-2.89 (m, 4H) 2.90-3.02 (m, 2H) 3.93-4.05 (m, 2H) 7.06-7.32 (m,12H) 8.01 (br. s., 1H)

2-fluoroethyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,944

1H NMR (300 MHz, Acetone-d6) δ ppm 1.73 (s, 6H) 1.91-2.02 (m, 2H)2.19-2.32 (m, 2H) 2.73-2.85 (m, 2H) 2.88-3.04 (m, 2H) 4.16-4.26 (m, 1H)4.25-4.36 (m, 1H) 4.44-4.55 (m, 1H) 4.60-4.68 (m, 1H) 7.09-7.31 (m, 12H)8.20 (br. s., 1H)

3-chloropropyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,945

1H NMR (300 MHz, Acetone-d6) δ ppm 1.73 (s, 6H) 1.89-2.03 (m, 2H)2.18-2.33 (m, 2H) 2.18-2.31 (m, 2H) 2.75-2.88 (m, 2H) 2.90-3.03 (m, 2H)3.58-3.70 (m, 2H) 4.08-4.19 (m, 2H) 7.03-7.32 (m, 12H) 8.11 (br. s., 1H)

Ethyl(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,354

1H NMR (300 MHz, Acetone-d6) δ ppm 1.15 (t, J=7.03 Hz, 3H) 1.74 (s, 6H)1.97-2.11 (m, 2H) 2.11-2.24 (m, 2H) 2.73-2.91 (m, 2H) 2.92-3.03 (m, 2H)3.94-4.08 (m, 2H) 7.08 (br. s., 2H) 7.12-7.35 (m, 10H) 7.98 (br. s., 1H)

Propyl(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,355

1H NMR (300 MHz, Acetone-d6) δ ppm 0.87 (t, J=7.33 Hz, 3H) 1.46-1.62 (m,2H) 1.74 (s, 6H) 1.98-2.09 (m, 2H) 2.10-2.23 (m, 2H) 2.82-2.91 (m, 2H)2.91-3.06 (m, 2H) 3.87-3.98 (m, 2H) 7.08 (s, 2H) 7.14-7.35 (m, 10H) 8.01(br. s., 1H)

Butyl(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,356

1H NMR (300 MHz, Acetone-d6) δ ppm 0.88 (t, J=7.33 Hz, 3H) 1.24-1.41 (m,2H) 1.47-1.60 (m, 2H) 1.74 (s, 6H) 1.97-2.11 (m, 2H) 2.08-2.24 (m, 2H)2.78-2.90 (m, 2H) 2.89-3.04 (m, 2H) 3.91-4.01 (m, 2H) 7.09 (br. s., 2H)7.13-7.34 (m, 10H) 8.00 (br. s., 1H)

3-chloropropyl(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,357

1H NMR (300 MHz, Acetone-d6) δ ppm 1.74 (s, 6H) 1.97-2.09 (m, 2H)2.11-2.25 (m, 2H) 2.79-2.93 (m, 4H) 2.91-3.04 (m, 2H) 3.56-3.72 (m, 2H)4.05-4.18 (m, 2H) 7.07 (br. s., 2H) 7.10-7.34 (m, 10H) 8.08 (s, 1H)

But-3-enyl(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,358

1H NMR (300 MHz, Acetone-d6) δ ppm 1.74 (s, 6H) 1.93-2.12 (m, 2H)2.11-2.23 (m, 2H) 2.23-2.37 (m, 2H) 2.81-2.90 (m, 2H) 2.91-3.06 (m, 2H)4.02 (t, J=6.74 Hz, 2H) 4.91-5.14 (m, 2H) 5.68-5.87 (m, 1H) 7.09 (br.s., 2H) 7.12-7.35 (m, 10H) 8.03 (br. s., 1H)

methyl(1S,7S)-1,7-bis(4-fluorophenyl)-1,7-dimethyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,674

¹H NMR (300 MHz, Acetone-d6): δ=1.71 (s, 6H) 1.92-2.07 (m, 2H) 2.19-2.27(m, 2H) 2.76-2.84 (m, 2H) 2.95-3.02 (m, 2H) 3.57 (s, 3H) 6.98-7.22 (m,10H)

butyl(1S,7S)-1,7-bis(4-fluorophenyl)-1,7-dimethyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate,672

¹H NMR (300 MHz, Acetone-d6): δ=0.88 (t, J=7.5 Hz, 3H) 1.51-1.56 (m, 2H)1.33-1.38 (m, 2H) 1.73 (s, 6H) 1.92-2.06 (m, 2H) 2.21-2.27 (m, 2H)2.81-2.84 (m, 2H) 2.94-3.27 (m, 2H) 3.97-4.43 (m, 2H) 6.98-7.22 (m, 10H)

S-methyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamothioate,583

¹H NMR (300 MHz, Acetone-d6): δ=1.68 (s, 6H) 2.02 (s, 3H) 2.20-1.88 (m,4H) 2.95-3.01 (m, 2H) 2.80-2.95 (m, 2H) 6.76 (s, 2H) 7.33-7.17 (m, 10H)

S-propyl(1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamothioate,585

¹H NMR (300 MHz, Acetone-d6): δ=0.91 (t, J=7.2 Hz, 3H), 0.97-1.1 (m, 2H)1.49-1.51 (m, 4H) 1.74 (s, 6H) 1.92-1.96 (m, 2H) 2.18-2.23 (m, 2H)2.73-2.84 (m, 4H) 2.95-3.05 (m, 2H) 7.05 (s, 2H) 7.15-7.36 (m, 8H)

S-methyl(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamothioate,582

¹H NMR (300 MHz, Acetone-d6): δ=1.73 (s, 6H) 2.20 (s, 3H) 1.98-2.07 (m,2H) 2.14-2.17 (m, 2H) 2.80-2.88 (m, 2H) 2.95-3.01 (m, 2H) 7.13-7.32 (m,12H)

S-propyl(1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamothioate,584

¹H NMR (300 MHz, Acetone-d6): δ=1.40 (t, J=9 Hz, 3H) 2.05-2.12 (m, 2H)2.28 (s, 6H) 2.66-2.72 (m, 6H) 2.51-2.64 (m, 2H) 3.47-3.54 (m, 2H)3.31-3.39 (m, 2H) 7.59-7.80 (m, 12H)

S-methyl(1S,7S)-1,7-bis(4-fluorophenyl)-1,7-dimethyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamothioate,671

¹H NMR (300 MHz, Acetone-d6): δ=1.73 (s, 6H) 2.19-2.21 (m, 2H) 2.24-2.27(m, 2H) 2.81 (s, 3H) 2.76-2.86 (m, 2H) 2.96-3.03 (m, 2H) 6.93-7.22 (m,10H)

S-propyl(1S,7S)-1,7-bis(4-fluorophenyl)-1,7-dimethyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamothioate,673

¹H NMR (300 MHz, Acetone-d6): δ=0.92 (t, J=9 Hz, 3H) 1.08-2.11 (m, 2H)1.50-1.60 (m, 4H) 1.70 (s, 6H) 1.90-1.98 (m, 1H) 2.17-2.25 (m, 3H)2.73-2.78 (m, 1H) 2.93-3.00 (m, 1H) 6.96-7.19 (m, 10H)

Example B Method B1: Preparation of1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-ethylurea(484)

To a solution1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-amine(Intermediate 4), (102 mg, 0.30 mmol) in dichloromethane (15 mL) wasadded ethyl isocyanate (0.026 mL, 0.33 mmol), mmol) under argon at 0° C.The reaction mixture was then stirred at room temperature for overnight.The solvent was removed under reduced pressure and purified by MPLC(medium pressure liquid chromatography) using silica gel column with 15to 20% EtOAc:Hexane to get1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-ethylurea(484) (120 mg 97%). ¹H NMR (300 MHz, CDCl₃) δ ppm 0.91 (t, J=7.18 Hz,3H) 2.05-2.20 (m, 2H) 2.21-2.39 (m, 2H) 2.96-3.28 (m, 6H) 4.07-4.19 (m,2H) 4.35 (br. s., 1H) 5.58 (s, 1H) 6.43 (s, 2H) 7.06-7.36 (m, 10H)

Method B2: Preparation of1-((1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-ethylurea,249

To a solution(1S,7S)-1,7-dimethyl-9-amino-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline(9), (110 mg, 0.30 mmol) in dichloromethane (15 mL) was added ethylisocyanate (0.026 mL, 0.328 mmol), mmol) under argon at 0° C. Thereaction mixture was then stirred at room temperature for overnight. Thesolvent was removed under reduced pressure and purified by MPLC) usingsilica gel column with 15 to 20% EtOAc:Hexane to get1-((1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-ethylurea(249), (96 mg 73%). 1H NMR (300 MHz, Acetone-d6) δ ppm 1.00 (t, J=7.18Hz, 3H) 1.71 (s, 6H) 1.91-2.02 (m, 2H) 2.15-2.31 (m, 2H) 2.75-2.87 (m,2H) 2.90-3.03 (m, 2H) 3.03-3.16 (m, 2H) 6.98 (s, 2H) 7.09-7.31 (m, 10H)

The following compounds were prepared according to the Reaction Scheme Band with the steps as shown in Example B above.

1-Butyl-3-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)urea,485

¹H NMR (300 MHz, CDCl₃) δ ppm 0.85 (t, J=7 Hz, 3H) 1.04-1.38 (m, 4H)2.05-2.19 (m, 2H) 2.19-2.38 (m, 2H) 2.89-3.29 (m, 6H) 4.14 (t, J=6.15Hz, 2H) 4.38 (br. s., 1H) 5.61 (s, 1H) 6.43 (s, 2H) 7.05-7.38 (m, 10H)

1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-pentylurea,486

¹H NMR (300 MHz, CDCl₃) δ ppm 0.84 (t, J=7.18 Hz, 3H) 1.03-1.33 (m, 6H)2.04-2.19 (m, 2H) 2.20-2.38 (m, 2H) 2.90-3.28 (m, 6H) 4.07-4.20 (m, 2H)4.38 (br. s., 1H) 5.58 (s, 1H) 6.43 (s, 5H) 7.07-7.39 (m, 10H)

1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-hexylurea,487

¹H NMR (300 MHz, CDCl₃) δ ppm 0.86 (t, J=7.1 Hz 3H) 1.06-1.33 (m, 8H)2.00-2.20 (m, 2H) 2.21-2.40 (m, 2H) 2.93-3.29 (m, 6H) 4.02-4.17 (m, 2H)4.29-4.45 (m, 1H) 5.57 (br. s., 1H) 6.43 (br. s., 2H) 7.03-7.40 (m, 10H)

1-(2-chloroethyl)-3-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)urea,769

¹H NMR (300 MHz, CD₃OD) δ ppm 1.99-2.15 (m, 2H) 2.19-2.35 (m, 2H)3.04-3.15 (m, 4H), 3.49 (m, 2H) 3.41-3.50 (m, 2H) 4.11-4.22 (m, 2H) 6.55(s, 2H) 7.09-7.21 (m, 5H) 7.21-7.32 (m, 5H)

1-allyl-3-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)urea,773

¹H NMR (300 MHz, CD₃OD) δ ppm 2.00-2.14 (m, 2H) 2.20-2.36 (m, 2H)3.04-3.16 (m, 4H) 3.58-3.69 (m, 2H) 4.11-4.23 (m, 2H) 4.94-5.13 (m, 1H)5.73 (m, 1H) 6.56 (s, 2H) 7.09-7.21 (m, 5H) 7.23-7.31 (m, 5H)

1-tert-butyl-3-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)urea,148

¹H NMR (300 MHz, CDCl₃) δ ppm 7.12-7.33 (m, 10H) 6.41 (s, 2H) 4.14 (t,J=6 Hz, 2H) 3.14-3.19 (m, 4H) 2.25-2.30 (m, 2H) 2.10-2.17 (m, 2H)2.25-2.33 (m, 2H)

1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-(furan-3-ylmethyl)urea,258

¹H NMR (300 MHz, CD₃OD) δ ppm 7.12-7.33 (m, 11H) 6.56 (s, 2H), 6.25-6.27(m, 1H) 6.08-6.10 (m, 1H) 4.19 (s, 2H) 4.16 (t, J=6 Hz, 2H) 3.07-3.12(m, 4H) 2.01-2.11 (m, 2H) 2.27-2.29 (m, 2H)

1-((1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-propylurea,250

¹H NMR (300 MHz, Acetone-d6) δ ppm 0.83 (t, J=6.8 Hz, 3H) 1.33-1.47 (m,2H) 1.72 (s, 6H) 1.88-2.02 (m, 2H) 2.17-2.30 (m, 2H) 2.77-2.88 (m, 2H)2.90-3.10 (m, 4H) 6.98 (s, 2H) 7.10-7.30 (m, 10H)

1-((1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-butylurea,251

¹H NMR (300 MHz, Acetone-d6) δ ppm 0.86 (t, J=6.8 Hz, 3H) 1.20-1.45 (m,4H) 1.70 (s, 6H) 1.90-2.02 (m, 2H) 2.15-2.30 (m, 2H) 2.79-2.88 (m, 2H)2.90-3.02 (m, 2H) 3.02-3.15 (m, 2H) 6.98 (s, 2H) 7.09-7.33 (m, 10H)

1-allyl-3-((1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)urea,252

¹H NMR (300 MHz, Acetone-d6) δ ppm 1.73 (s, 6H) 1.87-2.02 (m, 2H)2.16-2.30 (m, 2H) 2.74-2.87 (m, 2H) 2.89-3.01 (m, 2H) 3.67-3.78 (m, 2H)4.91-5.16 (m, 2H) 5.73-5.90 (m, 1H) 7.00 (s, 2H) 7.06-7.35 (m, 10H)

1-t-butyl-3-((1S,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)urea,581

¹H NMR (300 MHz, Acetone-d6): δ=0.71 (s, 9H) 1.20 (s, 6H) 1.97-2.02 (m,2H) 2.07-2.16 (m, 2H) 2.74-2.80 (m, 2H) 2.93-2.97 (m, 2H) 6.79 (s, 2H)7.36-7.17 (m, 10H)

1-((1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-ethylurea,463

¹H NMR (300 MHz, Acetone-d6) δ ppm 1.00 (t, J=7.18 Hz, 3H) 1.73 (s, 6H)1.94-2.03 (m, 2H) 2.10-2.25 (m, 2H) 2.79-2.90 (m, 2H) 2.92-3.04 (m, 2H)3.10 (t, J=6.45 Hz, 2H) 5.29 (br. s., 1H) 6.93 (s, 2H) 7.07-7.34 (m,10H)

1-((1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-propylurea,464

¹H NMR (300 MHz, Acetone-d6) δ ppm 0.82 (t, J=7.00 Hz, 3H) 1.31-1.48 (m,2H) 1.75 (s, 6H) 1.95-2.03 (m, 2H) 2.10-2.24 (m, 2H) 2.75-2.89 (m, 4H)2.92-3.07 (m, 2H) 5.33-5.35 (m, 1H) 6.95 (s, 2H) 7.07-7.35 (m, 10H)

1-((1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-butylurea,465

¹H NMR (300 MHz, Acetone-d6) δ ppm 0.86 (t, J=7.18 Hz, 3H) 1.19-1.44 (m,4H) 1.73 (s, 6H) 1.94-2.05 (m, 2H) 2.11-2.23 (m, 2H) 2.77-2.92 (m, 4H)2.92-3.02 (m, 2H) 3.02-3.12 (m, 2H) 5.31 (br. s., 1H) 7.09-7.34 (m, 10H)

1-t-butyl-3-((1R,7S)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)urea,580

¹H NMR (300 MHz, Acetone-d6): δ=1.26 (s, 9H) 1.71 (s, 6H) 1.57-1.71 (m,2H) 1.43-1.47 (m, 2H) 2.44-2.49 (m, 2H) 2.24-2.30 (m, 2H) 6.30 (s, 2H)6.64-6.84 (m, 10H)

Example C Method C: Preparation of3-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-1,1-dimethylurea(405)

To a solution1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-amine(Intermediate 4), (106 mg, 0.31 mmol) in dichloromethane (10 mL) wasadded triethyl amine (0.130 mL, 0.933 mmol) followed by dimethylcarbamicchloride (0.043 mL, 0.46 mmol), under argon at 0° C. The reactionmixture was then stirred at room temperature for overnight. The mixturewas quenched with water (30 mL). The residue was isolated in a typicalaqueous workup and purified by MPLC (medium pressure liquidchromatography) using silica gel column with 10 to 15% EtOAc:Hexane togive3-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-1,1-dimethylurea,(405), (63 mg 49%). ¹H NMR (300 MHz, CDCl₃) ppm 2.01-2.16 (m, 2H)2.20-2.37 (m, 2H) 2.85 (s, 6H) 3.00-3.15 (m, 4H) 4.12-4.25 (m, 2H) 5.78(s, 1H) 6.62 (s, 2H) 7.10-7.22 (m, 5H) 7.23-7.34 (m, 5H)

The following compound was prepared according to the Reaction Scheme Cand with the steps as shown in Example C above.

N-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)morpholine-4-carboxamide,983

¹H NMR (300 MHz, CDCl₃) δ ppm 2.03-2.17 (m, 2H) 2.20-2.38 (m, 2H)2.92-3.42 (m, 8H) 3.53-3.65 (m, 4H) 3.98-4.20 (m, 2H) 6.52-6.72 (m, 2H)7.08-7.23 (m, 5H) 7.24-7.37 (m, 5H)

Example D Method D: Preparation of1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-propylthiourea(255)

To a solution1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-amine(Intermediate 4), (100 mg, 0.294 mmol) in dichloromethane (15 mL) wasadded propyl isothiocyanate (0.038 mL, 0.323 mmol) under argon at 0° C.The reaction mixture was then stirred at room temperature for overnight.The solvent was removed under reduced pressure and purified by MPLC(medium pressure liquid chromatography) using silica gel column with 15to 20% EtOAc:Hexane to get1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-propylthiourea(255) (64 mg 49%). ¹H NMR (300 MHz, CDCl₃) ppm 7.08-7.34 (m, 10H) 6.39(s, 2H) 4.11 (t, J=6 Hz, 2H) 3.32-3.46 (m, 2H) 3.16-3.23 (m, 4H)2.25-2.30 (m, 2H) 2.13-2.17 (m, 2H) 1.32-1.39 (m, 2H, 0.73 (t, J=6 Hz,3H)

The following compound was prepared according to the Reaction Scheme Dand with the steps as shown in Example D above.

1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-hexylthiourea,256

¹H NMR (300 MHz, CDCl₃) δ ppm 7.07-7.34 (m, 10H) 6.39 (s, 2H) 4.11 (t,J=6 Hz, 2H), 3.46-3.49 (m, 2H) 3.15-3.25 (m, 4H) 2.25-2.32 (m, 2H)2.11-2.18 (m, 2H) 1.17-1.31 (m, 8H) 0.87 (t, J=6 Hz, 3H)

Example E Method E: Preparation ofN-butyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide(481)

To a solution ethyl 4-aminobenzoate (11) (2.47 g, 15 mmol) inacetonitrile (10 mL) was added one equivalent of trifluoroacetic acid(1.71 g, 15 mmol). To this suspension was added with stirring aheterogeneous mixture of styrene (12), (8.6 mL, 75 mmol) and 37%formaldehyde solution (6.09 mL, 75 mmol) under argon gave yellowprecipitate. The precipitate had failed to redissolve after 30 min. ofstirring at room temperature, so the mixture was heated at reflux underargon for further 30 min, during which time the precipitate redissolved.The reaction mixture was cooled to room temperature. The residue wasisolated in a typical aqueous workup and purified by MPLC (mediumpressure liquid chromatography) using silica gel column with 10 to 15%EtOAc:Hexane to give ethyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxylate(13), (4.1 g 68%).

A solution of ethyl1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxylate(13), (4 g, 10 mmol), in EtOH (40 mL) was subjected to saponificationreaction using 2N NaOH (40 mL). The residue was isolated in a typicalaqueous workup and purified by MPLC (medium pressure liquidchromatography) using silica gel column with 30 to 40% EtOAc:Hexane togive1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxylicacid (14), (2 g 54%).

To a solution of1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxylicacid (14), (189 mg, 0.512 mmol) in dichloromethane (10 mL) were addedbutyl amine (0.027 mL, 0.512 mmol), EDCl (196 mg, 1.02 mmol), followedDMAP (4-(Dimethylamino)pyridine) (70 mg, 1.02 mmol) under argon at 0° C.The reaction mixture was then stirred at room temperature for overnight.The reaction was quenched with water (30 mL). The residue was isolatedin a typical aqueous workup and purified by MPLC (medium pressure liquidchromatography) using silica gel column with 25 to 30% EtOAc:Hexane togiveN-butyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide(481), (113 mg 52%). ¹H NMR (300 MHz, CDCl₃) ppm 1H NMR (300 MHz,Solvent) ppm 0.87 (t, J=6.0 Hz, 3H) 1.17-1.38 (m, 2H) 1.36-1.52 (m, 2H)2.03-2.17 (m, 2H) 2.18-2.36 (m, 2H) 3.06-3.37 (m, 6H) 4.21 (t, J=5.27Hz, 2H) 5.61-5.75 (m, 1H) 7.03-7.16 (m, 4H) 7.17-7.37 (m, 8H).

The following compounds were prepared according to the Reaction Scheme Eand with the steps as shown in Example E above.

N-methyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide,775

¹H NMR (300 MHz, CDCl₃) δ ppm 2.05-2.19 (m, 2H) 2.18-2.35 (m, 2H) 2.79(d, J=4.40 Hz, 3H) 3.08-3.27 (m, 4H) 4.15-4.25 (m, 2H) 5.78 (bs, 1H)7.05-7.16 (m, 4H) 7.16-7.26 (m, 2H) 7.25-7.35 (m, 6H)

1,7-diphenyl-N-propyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide,409

¹H NMR (300 MHz, CDCl₃) δ ppm 0.86 (t, J=7.47 Hz, 3H) 1.41-1.54 (m, 2H)2.02-2.16 (m, 2H) 2.15-2.34 (m, 2H) 3.06-3.30 (m, 6H) 4.20 (q, J=5.66Hz, 2H) 5.71 (br. s., 1H) 7.03-7.16 (m, 4H) 7.16-7.38 (m, 8H)

N-pentyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide,482

¹H NMR (300 MHz, CDCl₃) δ ppm 0.85 (t, J=6.89 Hz, 3H) 1.16-1.34 (m, 4H)1.37-1.52 (m, 2H) 2.04-2.17 (m, 2H) 2.17-2.35 (m, 2H) 3.07-3.35 (m, 6H)4.20 (q, J=5.96 Hz, 2H) 5.69 (br. s., 1H) 7.06-7.16 (m, 4H) 7.17-7.39(m, 8H)

N-(2-hydroxyethyl)-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide,777

¹H NMR (300 MHz, CD₃OD) δ ppm 2.03-2.16 (m, 2H) 2.18-2.33 (m, 2H)3.06-3.26 (m, 4H) 3.31-3.39 (m, 2H) 3.50-3.60 (m, 2H) 4.25 (t, J=5.13Hz, 2H) 7.06-7.36 (m, 21H)

N-ethyl-1,7-bis(3-fluorophenyl)-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide,611

¹H NMR (300 MHz, Acetone-d6) δ ppm 1.03 (t, J=7.18 Hz, 3H) 2.06-2.17 (m,2H) 2.20-2.35 (m, 2H) 3.05-3.34 (m, 6H) 4.29 (t, J=5.13 Hz, 2H)6.84-6.92 (m, 2H) 6.92-7.05 (m, 4H) 7.27-7.41 (m, 4H)

N-butyl-1,7-bis(3-fluorophenyl)-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide,593

¹H NMR (300 MHz, Acetone-d6) δ ppm 0.87 (t, J=6.9 Hz, 3H) 1.30-1.37 (m,2H) 1.44-1.51 (m, 2H) 2.09-2.17 (m, 2H) 2.18-2.35 (m, 2H) 3.20-3.27 (m,6H) 4.25-4.29 (m, 2H) 6.97-7.02 (m, 4H) 7.30-7.38 (m, 6H).

Example F Method F: Preparation ofN-ethyl-2-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)acetamide(371)

To a solution 2-(4-aminophenyl)acetic acid (15) (3.0 g, 19.84 mmol) inacetonitrile (10 mL) was added one equivalent of trifluoroacetic acid(1.53 ml, 19.84 mmol). To this suspension was added with stirring aheterogeneous mixture of styrene (12), (11.3 mL, 99.2 mmol) and 37%formaldehyde solution (9.0 mL, 99.2 mmol) under argon gave yellowprecipitate. The precipitate had failed to redissolve after 30 min. ofstirring at room temperature, so the mixture was heated at reflux underargon for further 30 min, during which time the precipitate redissolved.The reaction mixture was cooled to room temperature. The residue wasisolated in a typical aqueous workup and purified by MPLC (mediumpressure liquid chromatography) using silica gel column with 10 to 30%EtOAc:Hexane to give2-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)aceticacid (16), (1.9 g, 48%).

To a solution of2-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)aceticacid (16), (85 mg, 0.229 mmol) in dichloromethane (10 mL) were addedEthyl amine (0.015 mL, 0.229 mmol), EDCl (103 mg, 0.538 mmol), followedby HOBt (72 mg, 0.538 mmol) under argon at 0° C. The reaction mixturewas then stirred at room temperature for overnight. The reaction wasquenched with water (30 mL). The residue was isolated in a typicalaqueous workup and purified by MPLC (medium pressure liquidchromatography) using silica gel column with 5% MeOH:CH₂Cl₂ to giveN-ethyl-2-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)acetamide(371), (27 mg, 29%).

¹H NMR (300 MHz, Acetone-d6) δ ppm 0.87 (t, J=6.9 Hz, 3H) 2.01-2.11 (m,2H), 2.21-2.27 (m, 2H) 3.0-3.6 (m, 8H), 3.20-3.27 (m, 6H) 4.25-4.29 (m,2H) 6.97-7.02 (m, 4H) 7.30-7.38 (m, 6H).

Example G Method G: Procedure for the methyl(4R,10R)-4,10-diphenyl-4,5,6,8,9,10-hexahydropyrido[3,2,1-de][1,5]naphthyridin-2ylcarbamate (179)

To a solution of N-(5-aminopyridin-2-yl)acetamide (Intermediate 1) (2.4g, 15.8 mmol) in acetonitrile (12 mL) was added one equivalent oftrifluoroacetic acid (1.2 mL, 15.8 mmol). To this suspension was addedwith stirring a heterogeneous mixture of styrene (Intermediate 2), (7.2mL, 63.2 mmol) and 37% formaldehyde solution (5.2 mL, 63.2 mmol) underargon, which gave a yellow precipitate. The precipitate failed toredissolve after 30 min. of stirring at room temperature, so the mixturewas heated at reflux under argon for further 30 min, during which timethe precipitate redissolved. The reaction mixture was cooled to roomtemperature. The precipitate was filtered and wash with acetonitrilegave yellow solid,n-((4R,10R)-4,10-diphenyl-4,5,6,8,9,10-hexahydropyrido[3,2,1-de][1,5]naphthyridin-2-yl)acetamide,(Intermediate 3), (2.78 g).

A mixture ofn-((4R,10R)-4,10-diphenyl-4,5,6,8,9,10-hexahydropyrido[3,2,1-de][1,5]naphthyridin-2-yl)acetamide,(Intermediate 3), (0.550 g, 1.43 mmol), in EtOH (12 mL) was Conc. HcL(1.2 mL). The mixture was stirred at 90° C. for two hrs. The mixture wasconcentrated, neutralized with aq. NaOH and extracted in CH₂Cl₂, dried(MgSO₄), filtered and concentrated gave(4R,10R)-4,10-diphenyl-4,5,6,8,9,10-hexahydropyrido[3,2,1-de][1,5]naphthyridin-2-amine(Intermediate 4) as a solid, (0.380 g).

To a solution(4R,10R)-4,10-diphenyl-4,5,6,8,9,10-hexahydropyrido[3,2,1-de][1,5]naphthyridin-2-amine(Intermediate 4), (110 mg, 0.322 mmol) in dichloromethane (10 mL) wasadded two equivalent of triethyl amine (0.090 mL, 0.644 mmol), followedby methyl chloroformate (0.037 mL, 0.483 mmol) under argon at 0° C. Thereaction mixture was then stirred at room temperature for overnight. Themixture was quenched with water (30 mL). The residue was isolated in atypical aqueous workup and purified by MPLC (medium pressure liquidchromatography) using silica gel column with 10 to 15% EtOAc:Hexane togive methyl(4R,10R)-4,10-diphenyl-4,5,6,8,9,10-hexahydropyrido[3,2,1-de][1,5]naphthyridin-2-ylcarbamate,(179), (20 mg). ¹H NMR (300 MHz, CDCl₃) δ ppm 2.00-2.18 (m, 2H)2.22-2.39 (m, 2H) 3.03-3.22 (m, 4H) 3.50-3.64 (m, 3H) 3.54-3.65 (m, 3H)4.05-4.23 (m, 2H) 6.61 (br. s., 2H) 7.08-7.38 (m, 10H)

Biological Data:

The compounds of the invention are assessed for their ability toactivate or block activation of the human S1P3 receptor in T24 cellsstably expressing the human S1P3 receptor using the method described inparagraph [0067] of United States Patent Application Publication No.20070232682, which published on Oct. 4, 2007, which is herebyincorporated by reference in its entirety.

Ten thousands cells/well are plated into 384-well poly-D-lysine coatedplates one day prior to use. The growth media for the S1P3 receptorexpressing cell line is McCoy's 5A medium supplemented with 10%charcoal-treated fetal bovine serum (FBS), 1% antibiotic-antimycotic and400 μg/ml geneticin. On the day of the experiment, the cells are washedtwice with Hank's Balanced Salt Solution supplemented with 20 mM HEPES(HBSS/Hepes buffer). The cells are then dye loaded with 2 μM Fluo-4diluted in the HBSS/Hepes buffer with 1.25 mM Probenecid and incubatedat 37° C. for 40 minutes. Extracellular dye is removed by washing thecell plates four times prior to placing the plates in the FLIPR(Fluorometric Imaging Plate Reader, Molecular Devices). Ligands arediluted in HBSS/Hepes buffer and prepared in 384-well microplates. Thepositive control, Sphingosine-1-phosphate (S1P), is diluted inHBSS/Hepes buffer with 4 mg/ml fatty acid free bovine serum albumin. TheFLIPR transfers 12.5 μl from the ligand microplate to the cell plate andtakes fluorescent measurements for 75 seconds, taking readings everysecond, and then for 2.5 minutes, taking readings every 10 seconds.Compounds are tested over the concentration range of 0.61 nM to 10,000nM. Data for calcium ion (Ca⁺²) responses are obtained in arbitraryfluorescence units and not translated into Ca⁺² concentrations. IC₅₀values (nM) are determined through a linear regression analysis usingthe Levenburg Marquardt algorithm.

Table I lists the test results for some of the compounds of the presentinvention:

TABLE 1 Biological Data: Activity Potency of Compounds against HumanS1P3 Receptor nM, (IC₅₀), % Inhibition: S1P3 S1P3 Comp. no. StructureIC₅₀ % Inhibition 272

8.3 102 273

63 101 274

64 100 275

12.2 100 276

8.7 101 277

901 91 278

66 101 484

77 101 485

52 100 486

82 100 487

301 100 405

131 98 983

130 100 769

374 100 773

160 100 094

234 101 093

48 102 (+)-enantiomer

3 97 (−)-enantiomer

230 97 202

272 98 779

23 101 268

5 98 (+)-enantiomer

1.6 98 (−)-enantiomer

NA 095

56 102 067

8 98 (+)-enantiomer

3 99 (−)-enantiomer

NA 354

16 97 353

13 98 352

40 97 206

62 100 205

8 99 (+)-enantiomer

4 99 (−)-enantiomer

1659 699

4 100 (+)-enantiomer

1.6 98 (−)-enantiomer

NA 700

7 100 (+)-enantiomer

13 98 (−)-enantiomer

NA 148

38 101 258

59 100 256

78 100 255

153 99 829

7 97 941

13 100 942

72 100 943

75 100 944

27 100 945

68 100 354

36 98 355

316 98 674

46 96 672

86 89 583

10 98 585

5 98 582

4 99 584

16 98 671

25 97 673

62 97 249

194 100 250

523 100 581

349 98 580

62 99 775

619 100 409

874 89 481

210 98

TABLE 2 Additional Compounds of the Present Invention: Com- poundStructure 1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54 (+) Single enantiomer

55 (−) Single enantiomer

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

The invention claimed is:
 1. A method of facilitating ocular woundhealing in a mammal, or of treating a disease or condition selected frommacular degeneration, retinal edema, retinal degeneration, idiopathicpulmonary fibrosis, diabetic retinopathy, optic neuropathy, andglaucomatous retinopathy in a mammal in need of such treatment,comprising administering to said mammal a pharmaceutical compositioncomprising a substituted hydropyrido-quinoline represented by thestructural formula:

wherein: Y is C or N; X is oxygen, sulfur or NR^(N); R^(N) is H or C₁₋₆alkyl; B is C₁₋₆ alkyl, C₁₋₆ alkenyl or C₁₋₆ alkyl having at least onehalo atom of F, Cl, Br, or I as substituent; R³ is hydrogen or C₁₋₆alkyl; each R¹ is independently hydrogen or C₁₋₆ alkyl; each R² isindependently substituted or unsubstituted phenyl; in combination withat least one additional component selected from the group consisting ofone or more emulsifying agent, wetting agent, sweetening agent,flavoring agent, tonicity adjuster, preservative, buffer, anti-oxidantand combinations thereof.
 2. The method according to claim 1, whereinthe substituted hydropyrido-quinoline is selected from:


3. The method of claim 1, wherein the disease or condition is idiopathicpulmonary fibrosis.
 4. The method of claim 1, wherein the disease orcondition is ocular wound healing.
 5. The method of claim 1, wherein thedisease or condition is retinal edema.
 6. The method of claim 1, whereinthe disease or condition is diabetic retinopathy.
 7. The method of claim1, wherein the disease or condition is optic neuropathy.
 8. The methodof claim 1, wherein the disease or condition is glaucomatousretinopathy.